SAN MATEO, Calif.--(BUSINESS WIRE)--EndoGastric Solutions® (EGS), a leader in advanced, endoscopic, reconstructive therapy for gastroesophageal reflux disease (GERD), today announced the company will introduce gastroenterologists to the Transoral Incisionless Fundoplication (TIF®) procedure during a hands-on demonstration at Digestive Disease Week (DDW®) in Washington, DC.
The hands-on demonstration will take place on Sunday, May 17 from 11 a.m. to 1 p.m. ET at the ASGE Learning Center supported, in part, by an educational grant from Olympus Corporations of the Americas; equipment will be provided by the Endoscopy Division of FUJIFILM Medical Systems U.S.A. and PENTAX Medical.
In addition, Anthony Starpoli, MD, a New York gastroenterologist at Greenwich Village Gastroenterology, will speak about the recent data published for the TIF procedure at a Special Interest Group (SIG) meeting on Saturday, May 16 from noon to 1:30 p.m. during a combined panel session, called “Endoluminal Therapy for Esophageal Disease (ETED) & Gastroesophageal Reflux Disease (GERD).” Dr. Starpoli will present his viewpoints on the current and future state of GERD in “The Role of Endoscopic Fundoplication for GERD: Where We Are and Where Are We Going” in room 103B.
“Thousands of patients have already benefited from treatment with this newest advancement in GERD being showcased,” said Skip Baldino, President and CEO of EndoGastric Solutions. “We anticipate more well-selected patients with GERD will be treated with the recent acceptance of a Category 1 CPT® code with a unique procedure descriptor associated with the company’s TIF® procedure for reflux.”
The new CPT code will be effective January 1, 2016 and four key specialty medical societies jointly sponsored the application: the American Gastroenterological Association (AGA), American College of Gastroenterology (ACG), American Society for Gastrointestinal Endoscopy (ASGE) and the Society of American Gastrointestinal and Endoscopic Surgeons (SAGES).
About Digestive Disease Week® (DDW)
Digestive Disease Week® (DDW) is the largest international gathering of physicians, researchers and academics in the fields of gastroenterology, hepatology, endoscopy and gastrointestinal surgery. Jointly sponsored by the American Association for the Study of Liver Diseases (AASLD), the American Gastroenterological Association (AGA) Institute, the American Society for Gastrointestinal Endoscopy (ASGE) and the Society for Surgery of the Alimentary Tract (SSAT), DDW takes place May 16–19, 2015, at the Walter E. Washington Convention Center, Washington, DC. The meeting showcases more than 5,000 abstracts and hundreds of lectures on the latest advances in GI research, medicine and technology. More information can be found at www.ddw.org.
Gastroesophageal Reflux Disease (GERD) is a chronic condition in which the gastroesophageal valve (GEV) allows gastric contents to wash back up into the esophagus, causing heartburn and possible injury to the esophageal lining. The stomach produces hydrochloric acid and other digestive enzymes after a meal to aid in the digestion of food. The cells that line the stomach are coated with a protective mucus that can withstand gastric contents, while the cells that line the esophagus lack the same protection.
GERD is the most common gastrointestinal-related diagnosis made by physicians during clinical visits in the U.S. It is estimated that pain and discomfort from acid reflux impacts over 23 million people two or more times per week in the U.S. The standard recommendations for symptomatic GERD patients include lifestyle changes (e.g., diet, scheduled eating times, and sleeping positions) and escalating doses of prescription medications for prolonged periods of time. Long-term, maximum dose usage of prescription medications has been linked to a variety of other health complications.
About Transoral Incisionless Fundoplication (TIF®) procedure for reflux
Performed entirely through the mouth without the need for external incisions through the skin, the TIF procedure offers patients who require an anatomical change to correct the underlying cause of GERD, another treatment option beyond traditional surgery. Studies show that for up to three years after the TIF procedure esophageal inflammation (esophagitis) is eliminated and most patients are able to stop using daily PPI medications to control symptoms.
The TIF procedure has an established safety and efficacy profile with over 50 peer-reviewed publications detailing consistent outcomes on more than 800 unique patients. To date, more than 16,700 patients have been treated worldwide; for more information, visit www.GERDHelp.com.
About the EsophyX® device
The EsophyX device was FDA cleared in 2007, and is commercially available in the United States. Inserted through the patient’s mouth with visual guidance from an endoscope, the EsophyX device is used to reconstruct the gastroesophageal valve (GEV) in order to restore its function as a barrier to prevent stomach acids from washing back up into the esophagus.
About EndoGastric Solutions®
EndoGastric Solutions, Inc. (www.endogastricsolutions.com), is a leader in the endoluminal treatment of digestive diseases. EGS’ mission is to combine the most advanced concepts in gastroenterology and surgery to develop products and procedures that address unmet needs in gastrointestinal diseases.
The EsophyX device with SerosaFuse fasteners is indicated for use in transoral tissue approximation, full thickness plication and ligation in the GI tract and is indicated for the treatment of symptomatic chronic gastroesophageal reflux disease in patients who require and respond to pharmacological therapy. It is also indicated to narrow the gastroesophageal junction and reduce hiatal hernia <2 cm in size in patients with symptomatic chronic gastroesophageal reflux disease.